Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MonoSol Rx files false marking lawsuit against BDSI, Meda, Aveva
MonoSol Rx’s complained that BDSI, MEDA, and Aveva’s manufacture, marketing, and sale of the Onsolis film products infringe MonoSol Rx’s US patent no 7,824,588 related to methods of
MonoSol Rx’s complained that BDSI, MEDA, and Aveva’s manufacture, marketing, and sale of the Onsolis film products infringe MonoSol Rx’s US patent no 7,824,588 related to methods of
Cambrex is a provider of products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company also offers Active Pharmaceutical Ingredients (APIs), advanced
Under the terms of agreement, Kyoto University and Takeda will work closely to discover new drug targets and biomarkers for obesity and schizophrenia. The two parties will conduct
Based on the analysis of 552 PFS events in 711 patients, the study achieved its primary endpoint with a statistically significant 28% reduction in the risk of progression
The tie up allows Ironwood Pharma to develop new peptides and treatments for therapeutic areas with unmet medical needs. During the collaboration period, Protagonist will use its disulfide
Amgen‘s 100,000sqft manufacturing facility houses process development labs with pilot plant and currently employs 360 employees. Amgen has acquired Fremont facility through its 2006 acquisition of Abgenix. Boehringer
Extedo is a solutions and services provider in the field of eRegulatory Affairs. Extedo claims that its eCTDmanager Suite is an easy-to-use electronic management solution for building, viewing,
Harbor BioSciences retains the rights to these products in US and rest of the world, and CIPI will provide the company all the pre-clinical and clinical data it
Microbix Biosystems is a biotechnology company commercializing novel technologies for influenza vaccine manufacturing and livestock semen sexing, in addition to a core business of virology products. Earlier, Baron
CureFAKtor Pharma is intending to conduct a Phase I clinical study of CFAK-C4 in combination with gemcitabine chemotherapy in 2012. CureFAKtor Pharma president and CEO Shep Wild said